Inflammatory processes have an important role in the development of hepatic steatosis and progression to nonalcoholic steatohepatitis (NASH). Interleukin-6 (IL-6) is known to be a proinflammatory cytokine, but also promotes liver regeneration and protects the liver against various forms of damage. The role of IL-6/Glycoprotein130 (GP130) in NASH remains unclear. In this study, we determined whether blocking IL-6/GP130 signaling prevents progression of steatohepatitis in a mouse NASH model. Six-week-old male C57/BL6 mice were fed either chow control or a methionine cholinedeficient (MCD) diet for 8 weeks. Half of the MCD diet-fed mice were treated with 15 mg/kg rat anti-mouse IL-6 receptor antibody (MR16-1), intraperitoneally twice weekly, the remainder and chow-fed mice were injected with 15 mg/kg rat IgG as a control. Hepatic steatosis, injury, fibrosis, apoptosis, markers of lipid peroxidation/oxidant stress and IL-6-related gene expressions were evaluated. MR16-1 treatment decreased signal transducer and activator of transcription 3 activities and expression of suppressor of cytokine signaling 3 in MCD diet-treated mouse livers. Although this treatment enhanced intrahepatic lipid accumulation accompanied by increased sterol regulatory element-binding protein 1 and decreased peroxisome proliferator-activated receptor-a expression, elevated plasma alanine aminotransferase levels were improved with decreased plasma free fatty acid levels, lipid peroxidation/oxidant stress and hepatic apoptosis. Blocking IL-6/GP130 signaling by MR16-1 enhanced MCD diet-induced hepatic steatosis, but ameliorated liver injury. These findings suggest that hepatic IL-6 signaling has a protective role against the progression of hepatic steatosis but may enhance liver inflammation.
Inflammatory processes have an important role in the development of hepatic steatosis and progression to nonalcoholic steatohepatitis (NASH). Interleukin-6 (IL-6) is known to be a proinflammatory cytokine, but also promotes liver regeneration and protects the liver against various forms of damage. The role of IL-6/Glycoprotein130 (GP130) in NASH remains unclear. In this study, we determined whether blocking IL-6/GP130 signaling prevents progression of steatohepatitis in a mouse NASH model. Six-week-old male C57/BL6 mice were fed either chow control or a methionine cholinedeficient (MCD) diet for 8 weeks. Half of the MCD diet-fed mice were treated with 15 mg/kg rat anti-mouse IL-6 receptor antibody (MR16-1), intraperitoneally twice weekly, the remainder and chow-fed mice were injected with 15 mg/kg rat IgG as a control. Hepatic steatosis, injury, fibrosis, apoptosis, markers of lipid peroxidation/oxidant stress and IL-6-related gene expressions were evaluated. MR16-1 treatment decreased signal transducer and activator of transcription 3 activities and expression of suppressor of cytokine signaling 3 in MCD diet-treated mouse livers. Although this treatment enhanced intrahepatic lipid accumulation accompanied by increased sterol regulatory element-binding protein 1 and decreased peroxisome proliferator-activated receptor-a expression, elevated plasma alanine aminotransferase levels were improved with decreased plasma free fatty acid levels, lipid peroxidation/oxidant stress and hepatic apoptosis. Blocking IL-6/GP130 signaling by MR16-1 enhanced MCD diet-induced hepatic steatosis, but ameliorated liver injury. These findings suggest that hepatic IL-6 signaling has a protective role against the progression of hepatic steatosis but may enhance liver inflammation. Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide. 1 According to the two-hit hypothesis for NAFLD progression, hepatic steatosis is a risk factor for nonalcoholic steatohepatitis (NASH) and fibrosis. 2 Continuous excess triglyceride accumulation induces proinflammatory cytokines, produces reactive oxygen species (ROS) and leads to NASH. Proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-a) and interleukin (IL)-6, are believed to have a central role in this process. Plasma TNF-a levels have been reported to be higher in patients with NASH than in patients with steatosis and controls with no known liver diseases. 3, 4 In vivo studies have shown that treatment of leptin-deficient ob/ob mice with antibodies against TNF-a improved NASH and hepatic insulin resistance. Mice genetically deficient in the TNF type 1 receptor were resistant to steatosis and liver injury induced by a highcarbohydrate and a methionine choline-deficient (MCD) diet. 5 Although cytokine imbalance and, in particular, an increase in TNF-a may have a key role in the development of NASH, the role of IL-6 remains obscure. IL-6 is a cytokine with numerous effects, which are dependent on TNF-a acting as an upstream mediator. 6, 7 Previous studies have shown that, despite no significant difference between fatty liver and NASH patients, inflammatory C-reactive protein (CRP) was increased in both liver and adipose tissues in patients with severe obesity. Basically, CRP mRNA levels are correlated positively with those of IL-6 and the liver, and also adipose tissue, and can produce CRP, a process which could be dependent on IL-6. 8 These findings suggest a role for IL-6 as a proinflammatory cytokine in the development of NASH. Moreover, latest reports have shown that hepatocyte IL-6 expression correlated positively with plasma IL-6 levels and the degree of hepatic inflammation, stage of fibrosis and systemic insulin resistance. 3, 4, 9 From a different point of view, IL-6 is well known to be a hepato-protective cytokine. IL-6 acts directly on hepatocytes, inducing the translocation of signal transducer and activator of transcription (STAT)3 to the nucleus causing early gene activation and mitosis. 10, 11 The IL-6/soluble IL-6 receptor fusion protein led to an earlier onset of hepatocellular proliferation and had an important role in liver regeneration after partial hepatectomy in mice. 12 This signaling not only has an effect on hepatocyte proliferation but also protects the liver against various forms of injury, such as ischemia and reperfusion, toxins, alcohol and death-mediated Fas activation. [13] [14] [15] Mice lacking IL-6 have an impaired ability to regenerate their livers after partial hepatectomy, increased caspase 3/8 activities and reduced antiapoptotic mediators. 6, 14, 16, 17 Short-term replacement of IL-6 also might protect the liver through preservation and restoration of intrahepatic adenosine triphosphate (ATP) levels, which have been reported to be reduced in fatty livers. 18 Chronic inflammation is a risk for the development of fibrosis and carcinogenesis in various organs. 19, 20 Controlling the inflammation would prevent the progression of this process, even if it may not be able to stop the occurrence of the diseases altogether. Recently, inhibition of the proinflammatory cytokine signaling pathway using neutralizing antibody against the IL-6 receptor (tocilizumab, which is a specific antagonist of the human IL-6 receptor and soluble IL-6 receptor) has been reported to improve chronic inflammatory diseases, such as rheumatoid arthritis, in clinical practice. 21 In this study, to evaluate the possible role of IL-6 in the development of hepatic steatosis and NASH, we tested a rat anti-mouse IL-6 receptor antibody, MR16-1, a specific antagonist of the mouse IL-6 receptor, in mouse NASH models. Feeding mice with an MCD diet induces steatohepatitis and liver fibrosis, providing a useful small animal model for NASH. 22 Using this model, we found that, although treatment with MR16-1 enhanced hepatic steatosis, it ameliorated liver injury. Neutralizing the IL-6 receptor by MR16-1 for 8 weeks suppressed IL-6/ Glycoprotein130 (GP130) signaling successfully and decreased expression of suppressor of cytokine signaling (SOCS)3 in correlation with decreased plasma free fatty acid (FFA) levels, hepatic Cyp2E1 expression, evidence of lipid peroxidation/oxidant stress and hepatocyte apoptosis. In conclusion, inhibiting IL-6/GP130 signaling enhanced hepatic steatosis, but ameliorated liver damage in mice with MCD diet-induced NASH.
MATERIALS AND METHODS Animals and Treatments
A mouse model of MCD diet-induced NASH was studied. Six-week-old male C57/BL6 mice were purchased from Japan Jackson Laboratories, maintained in a temperature-and light-controlled facility and permitted consumption of water ad libitum. In all, 5 mice were fed a control chow diet (cat no. 960441; ICN, Aurora, OH) and 10 were fed an MCD diet (cat no. 960439; ICN) for 8 weeks. Half of the MCD diet-fed mice (N ¼ 5) were treated with 15 mg/kg rat anti-mouse IL-6 receptor antibody (MR16-1; Cyugai Pharmaceutical, Tokyo, Japan) intraperitoneally twice weekly, the remainder (N ¼ 5) and five chow-fed mice were injected with control rat IgG (Equitech-Bio, Kerrville, TX). 23, 24 All animal experiments fulfilled the requirements for humane animal care in the Kyoto Prefectural University of Medicine.
Immunoblot Assay
Nuclear proteins isolated using a NE-PER Nuclear Extraction Reagent Kit (Pierce Biotechnology, Rockford, IL) and proteins isolated from whole livers were electrophoresed in SDS-PAGE gels and transferred to PVDF membranes. The membranes were probed with anti-sterol regulatory element-binding protein (SREBP)-1 (Santa Cruz Biotechnology, sc-366 for the precursor and sc-367 for the mature fragment, Santa Cruz, CA), anti-peroxisome proliferator-activated receptor (PPAR)a (LifeSpan Biosciences, WA), anti-4-hydroxy-2-nonenal (HNE) (HNEJ-2; Nikken, Shizuoka, Japan), anti-cytochrome P4502E1 (Cyp2E1) (Stressgen, Victoria, Canada), anti-catalase (Abcam, Cambridge, MA) anti-STAT3, anti-phospho-STAT3, anti-Akt, anti-phospho-Akt (ser473), anti-adenosine monophosphateactivated protein kinase (AMPK), anti-phospho-AMPK (Thr172), (Cell Signaling Technology, Beverly, MA) antibody, anti-a-actin (Santa Cruz Biotechnology) antibody or antiglyceraldehydes-3-phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology) antibody, followed by horseradish peroxidase (HRP)-conjugated anti-mouse or rabbit IgG (Amersham, UK). Antigens were visualized by ECL (Amersham). Immunoblots were scanned, and band intensities were quantified by Image J (NIH) densitometry analysis.
Two-
Step Real-Time RT-PCR Real-time PCR was performed as described previously. 25 Specificity was confirmed for all primer pairs (Table 1) by sequencing the PCR products. Target gene levels are presented as a ratio of levels in treated vs corresponding control groups. Fold changes were determined using point and interval estimates.
Immunohistochemistry and Analysis of Liver Architecture Serial sections were stained with H&E using standard techniques. After deparaffinization, microwave antigen retrieval and blocking endogenous peroxidase activity, other sections were incubated with a TdT-mediated dUTP-digoxigenin nick-end labeling (TUNEL) reaction mixture, containing terminal deoxyribonucleotidyl transferase (TdT) and fluorescein-dUTP (Roche Diagnostic, Indianapolis, IN), or anti-asmooth muscle actin (SMA) (DakoCytomation, Carpinteria, CA) antibody. Antigen was demonstrated using secondary anti-mouse polymer HRP and DAB chromagen (DakoCytomation) and counterstaining with Gill's hematoxylin. The number of TUNEL-positive hepatocytes was counted in three randomly selected fields per section ( Â 100 magnification).
Quantification of Hepatic Collagen Content
Sirius red staining was performed on 4-mm-thick paraffin sections of liver tissues fixed in buffered formalin. After deparaffinization, the sections were treated with 0.1% Sirius Red F3B (Sigma-Aldrich, Japan) and 0.1% Fast Green FCF (Sigma-Aldrich) in saturated Picric acid solution (SigmaAldrich) for 30 min. Sirius red staining area was quantitated by Image J software in three randomly selected fields per section ( Â 200 magnification).
Tissue and Plasma Biochemical Measurements
Plasma alanine aminotransferase (ALT), FFA, total cholesterol, triglyceride and glucose levels were measured as described previously. 25 Plasma IL-6, serum amyloid A (SAA), TNF-a concentrations and tissue triglyceride were measured using an IL-6 Mouse ELISA Kit (R&D Systems, Minneapolis, MN), SAA mouse ELISA kit (Stressgen), TNF-a mouse ELISA Kit (Invitrogen, Japan) and Triglyceride Detection Kit (Sigma-Aldrich) according to the manufacturers' instructions.
Statistical Analysis
Results are expressed as mean ± s.e.m. Significance was established using Student's t-test and analysis of variance when appropriate. Differences were considered significant when Po0.05.
RESULTS

An MCD Diet Elevated Plasma IL-6 Levels and Activated Hepatic STAT3 Signaling
We measured plasma IL-6 levels by ELISA in MCD diet-fed mice and compared them with those in chow diet-fed mice. As in previous studies, 26, 27 an MCD diet increased IL-6 levels dramatically ( Figure 1a) and also activated the expression of a key gene in IL-6/GP130 signaling, STAT3 (Figure 1b) . Plasma SAA levels were also increased in MCD diet-fed mice Blockade of IL-6 receptor in MCD diet-fed mice K Yamaguchi et al ( Figure 1c ). The expression of genes involved in glucogenesis and lipogenesis, Akt and AMPK, was also assessed. An MCD diet induced AMPK phosphorylation but reduced Akt phosphorylation (Figure 1b) . Furthermore, mRNA levels of hepatic SOCS3 were slightly (but not significantly, P ¼ 0.094) increased in MCD mice (Figure 1d ), suggesting that activation of STAT3 by an MCD diet might inhibit Akt phosphorylation through induction of SOCS3.
Neutralizing the IL-6 Receptor Blocked IL-6/GP130 Signaling In this study, we used MR16-1 to block the IL-6/GP130 pathway because earlier studies had shown that twice weekly intraperitoneal injections of 15 mg/kg MR16-1 suppressed the IL6/GP130 pathway in mice effectively. 24 First, to examine the efficacy of MR16-1, we measured plasma IL-6 concentrations after MR16-1 treatment, and found that plasma IL-6 levels were greatly increased. This phenomenon may be caused by decreased clearance of IL-6 from the blood 28 and suggests that MR16-1 treatment blocked the IL-6 receptor successfully (Figure 2a , Supplementary Figure 1A ). This treatment had little effect on STAT3 phosphorylation in chow-fed controls but greatly decreased MCD diet-induced STAT3 phosphorylation (Figure 2b,  Supplementary Figure 1B) . This result showed that profound suppression of hepatic STAT3 activity might be attributed to the inhibition of IL-6 signaling by MR16-1 treatment in MCD diet-fed mice. Moreover, Akt phosphorylation was somewhat recovered by MR16-1 treatment in both chowand MCD diet-fed mice. In contrast, AMPK phosphorylation seems slightly decreased in MCD diet-fed mice (Figure 2b,  Supplementary Figure 1B) . MR16-1 treatment had no effect on plasma SAA levels in chow-fed mice, but slightly decreased plasma SAA levels in MCD diet-fed mice (Figure 2c,  Supplementary Figure 1C) . mRNA levels of hepatic SOCS3 expression were also decreased by 450% in only MCD dietfed mice (Figure 2d, Supplementary Figure 1D , *Po0.05).
Neutralizing the IL-6 Receptor Exacerbated MCD DietInduced Hepatic Steatosis, but it Decreased Plasma FFA Levels As some reports have shown that the activation of STAT3 improved hepatic steatosis by inhibiting expression of SREBP-1, 11, 29 neutralizing the IL-6 receptor might be expected to exacerbate hepatic steatosis. This was evaluated by H&E staining. Steatosis was scored on H&E-stained sections according to Brunt's criteria 30 and photomicrographs from representative mice are shown (Figure 3a , Supplementary  Figure 2A ). An MCD diet for 8 weeks induced a mild diffuse hepatic steatosis compared with chow diet. Furthermore, Figure 2 The effect of MR16-1 treatment on plasma IL-6 levels and hepatic IL-6/GP130-related gene expression in MCD diet-fed mice. (a) Plasma IL-6 levels were measured. Mean±s.e. data from each MCD diet-fed group (n ¼ 5 per group) are plotted at 8 weeks. (b) P-STAT3, STAT3, p-Akt, Akt, p-AMPK and AMPK levels were evaluated by immunoblot analysis of livers obtained from three mice per group after 8 weeks. To control for loading, the blot was stripped and reprobed for b-actin. P-STAT3/t-STAT3, P-Akt/t-Akt and p-AMPK/t-AMPK ratios in each group were also expressed as fold change of control IgG-treated mice (*Po0.05). (c) Plasma SAA levels were measured. Mean ± s.e. data from each group (n ¼ 5 per group) are plotted at 8 weeks. (d) mRNA levels of hepatic SOCS3 were determined by quantitative real-time PCR analysis after 8 weeks of treatment. Results were normalized to GUS expression and then expressed as fold change relative to gene expression in controls. Mean±s.e. data from each MCD diet-fed group (n ¼ 5 per group) (*Po0.05).
Blockade of IL-6 receptor in MCD diet-fed mice K Yamaguchi et al Blockade of IL-6 receptor in MCD diet-fed mice K Yamaguchi et al MCD diet-fed, but not chow-fed, mice treated with MR16-1 had a greater degree of hepatic steatosis than those treated with control IgG. These findings were confirmed by analysis of body weight (BW), liver/BW ratio and biochemical analysis of hepatic triglyceride content (Figure 3b , Supplementary Figure 2B ). Interestingly, MR16-1 treatment attenuated the MCD diet-induced increases in plasma FFA without decreasing plasma triglyceride and total cholesterol levels ( Figure 3c, Supplementary Figure 2C ).
Neutralizing the IL-6 Receptor Enhanced Hepatic Fatty Acid Synthesis and Uptake
We assessed the protein levels of SREBP-1 expression to investigate their correlation with decreased STAT3 activity and exacerbated hepatic steatosis after MR16-1 treatment. An MCD diet had no effect on the SREBP-1 precursor (molecular weight: 125 kDa) that is attached to the nuclear envelope and endoplasmic reticulum but slightly decreased the mature soluble fragment (molecular weight: 68 kDa) in the nucleus (Figure 4a ). MR16-1 treatment increased both forms of SREBP-1 in MCD diet-fed mouse livers (Figure 4a ). An MCD diet decreased the protein levels of PPARa, and MR16-1 treatment further accelerated the reduction (Figure 4b ). In our study, although the fatty acid transport protein (FATP) 3, 4 (data not shown) and 5 mRNA levels were not altered, FATP 1 and 2 were significantly upregulated in MCD diet-fed mice (but not significantly in chow-fed mice) by MR16-1 treatment (Figure 4c , *Po0.05, Supplementary Figure 3C ).
Neutralizing the IL-6 Receptor had no Effect on MCD Diet-Induced Liver Fibrosis
Hepatic steatosis has been identified as a risk factor for liver fibrosis. Therefore, we assessed liver fibrosis by real-time PCR of mRNA levels of various markers of fibrosis. Although an MCD diet significantly increased mRNA levels of hepatic collagen and transforming growth factor b1 expression, compared with chow control, MR16-1 treatment had no effect on those levels (Figure 5a , *Po0.05). Sirius red staining and a-SMA immunohistochemistry were performed to further assess the effects of MCD diet and MR16-1 treatment on liver fibrosis. However, MR16-1 treatment had no effect on the area of Sirius red-stained fibrils and a-SMA staining cells (Figure 5b ).
Neutralizing the IL-6 Receptor Ameliorated MCD DietInduced Liver Injury To evaluate liver injury after MR16-1 treatment, we compared injury-related parameters. As expected, MCD diet-fed mice exhibited 10-fold higher plasma ALT values than did the controls (Figure 6a ). However, plasma ALT values were Figure 3A) . In many mouse models of fatty liver diseases and insulin resistance, as well as in humans with similar conditions, TNF-a has been implicated to have an important role in the pathogenesis of NASH. In this study, however, MR16-1 treatment had little effect on MCD diet-induced elevated plasma TNF-a levels and hepatic TNF-a mRNA expression (Figure 6b, Supplementary Figure 3B ). Liver sections were also evaluated for lobular inflammation. The lobular inflammatory grade was higher in MCD diet-fed mice than in chow-fed controls. MR16-1 treatment slightly ameliorated liver injury in MCD diet-fed mice (Figure 6c ). To determine why neutralizing the IL-6 receptor in MCD diet-fed mice ameliorated liver injury but exacerbated liver steatosis, we compared the expression of microsomal and peroxisomal FFA-oxidizing enzymes and markers of lipotoxicity. MR16-1 treatment decreased protein levels of hepatic Cyp2E1, catalase and MCD diet-induced 4-HNE expression (Figure 6d) . Furthermore, TUNEL staining also showed that MCD dietinduced hepatic apoptosis was decreased by MR16-1 treatment (Figure 6e ).
DISCUSSION
According to the 'two-hit' hypothesis, oxidative stress, lymphocyte activation and cytokine release are candidate elements of the pathogenic transition from simple steatosis to steatohepatitis. 2 We focused on the role of IL-6 as a proinflammatory cytokine and used an inhibitor of the IL-6 receptor, MR16-1, in an MCD diet-induced NASH model, because an MCD diet was found to increase plasma IL-6 levels significantly and to activate hepatic IL6/GP130-related gene expression. Consequently, treatment of these mice with MR16-1 enhanced hepatic steatosis but ameliorated liver cell injury.
These contrasting observations regarding hepatic steatosis and inflammation indicate a paradoxical role for IL-6 in the development of chronic steatosis and inflammation of the liver. Recently, Horiguchi et al reported that, although STAT3 in hepatocytes, which depends on IL-6, could contribute to promote liver inflammation but inhibit steatosis by inhibiting SREBP-1 expression directly, STAT3 in macrophages/ Kupffer cells, which depends on IL-10, could suppress liver inflammation during alcoholic liver injury. 29 This report reinforces our results. In our study, MR16-1 treatment blocked the MCD diet-induced hepatic STAT3 activation ( Figure 2b ) and ameliorated liver cell injury (Figure 6a) . Interestingly, MR16-1 treatment also induced greater hepatic steatosis accompanied by increased hepatic SRBP-1 expression (Figures 3a and 4a) . Further study regarding STAT3 activation in isolated hepatic macrophages/Kupffer cells obtained from MCD-diet fed mice and the effects of IL-10 is recommended in the future. The role of IL-6 in the pathogenesis of NAFLD has been an issue of debate. Although IL-6 is well known as one of several proinflammatory cytokines active during infection, cahexia and obesity, IL-6 also is protective against various forms of liver damage. [4] [5] [6] [7] [10] [11] [12] [13] [14] [15] [16] [17] According to the paper by Wallenius et al, 31 IL-6-deficient mice develop mature-onset obesity, which is reversed by IL-6 replacement. This finding is interesting and also reinforces our data that blocking IL-6/GP130 Blockade of IL-6 receptor in MCD diet-fed mice K Yamaguchi et al signaling deteriorates hepatic steatosis in MCD-diet induced NASH model. Therefore, the therapeutic use of IL-6/GP130 signaling in treating obesity seems to be an attractive target of future investigation. Recently, however, elevated proinflammatory cytokines have been shown in mice with obesityrelated NASH. 9 These increased cytokines are believed to downregulate insulin signaling with increased SOCS3 protein in the liver. 32, 33 Some other previous reports have also shown that long-term IL-6 exposure induced SOCS3 expression, caused insulin resistance and exacerbated liver injury, whereas short-term IL-6 exposure prevented hepatocyte apoptosis and steatosis after CCl4 treatment or partial hepatectomy. 34, 35 Hence, we hypothesized that continuous IL-6 stimulation induced liver inflammation and fibrosis.
An MCD diet is believed to induce accumulation of hepatic triglycerides by inhibiting mitochondrial b-oxidation of fatty acids and blocking hepatic export of VLDL. 25 Unlike high-fat diets, which produce relatively little hepatic necroinflammation and fibrosis, MCD diets are used widely to induce NASH with fibrosis. Although an MCD diet inhibits mitochondrial oxidation of FA, thereby limiting that process as a source of ROS, this diet induces microsomal FA-oxidizing enzymes, such as Cyp2E1. The latter may produce sufficient ROS to trigger the secondary 'hits' that are required for progression from NAFLD to more advanced stages of fatty liver disease. 36, 37 Thus, MCD diets promote NASH with fibrosis, even in nonobese mice. Moreover, recent interesting reports have shown that not only decreased VLDL secretion but also increased fatty acid uptake and cytoplasmic fatty acid synthesis genes, despite decreased nuclear levels of lipogenic transcription factors, such as SREBP-1, are the major mechanisms by which the MCD diet promotes intrahepatic lipid accumulation. 38 These discrepancies in lipogenic gene expression between the nuclei and cytoplasm seem to be present at an earlier stage of MCD diet-induced NASH. In this study, an MCD diet for 8 weeks decreased all lipogenic gene expression, mRNA levels of SREBPs, AcetylCoA Carboxylase, ATP-citrate lyase, fatty acid synthase and Stearoyl-CoA desaturase-1 and protein levels of PPARa in the liver (data not shown).
An MCD diet increased hepatic AMPK phosphorylation (Figure 1b ). An MCD diet itself inhibits mitochondrial import of carnitine, thereby limiting FA oxidation that normally generates ATP. ROS/lipid peroxidation that results from alternative FA-oxidizing mechanisms also damages the mitochondria, further limiting ATP production. Gradual diet-related depletion of liver ATP pools activates AMPK. Furthermore, IL-6 also increases AMPK rapidly and markedly. 39, 40 AMPK regulates the expression of genes involved in lipogenesis and mitochondrial biogenesis and also inhibits cell survival by binding to and phosphorylating insulin receptor substrate (IRS)-1 at Ser794. 40 Phosphorylation of IRS-1 at this site inhibits phosphatidylinositol 3-kinase/Akt signaling, suppresses the mitochondrial membrane potential and promotes apoptosis. In this model, Akt signaling was considered to be inhibited by increased AMPK and STAT3-induced SOCS3. 11 Hence, it can be postulated that MR16-1 treatment contributed to the recovery of Akt activity, resulting in reduced hepatocyte apoptosis in this model.
In conclusion, MR16-1 treatment decreased SOCS3 expression successfully, suppressed STAT3 activation and improved plasma FFA elevation through increased fatty acid uptake and hepatic triglyceride biosynthesis, leading to decreased Cyp2E1 expression, ROS production and hepatic apoptosis. As shown by our previous study, hepatic triglyceride synthesis may have a compensatory role for an impaired mechanism of FFA detoxification. 25 In clinical trial with neutralizing IL-6 receptor antibody, it was reported that plasma triglyceride and cholesterol levels were elevated in treated patients with rheumatoid arthritis. 21, 41 It is interesting and necessary to investigate whether hepatic steatosis in those patients is ameliorated or exacerbated. Hopefully, further experiments using MR16-1 in other NASH models will show the effect of neutralizing IL-6 receptor on the hepatic histology in NASH.
